During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of ...

During a live event, Tian Zhang, MD, MHS, discussed darolutamide in mHSPC, with efficacy and cost being key considerations ...

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing ...

The COCOON study reveals a new dermatology management strategy that significantly reduces skin-related adverse effects in ...

New 5-year data reveals cemiplimab plus chemotherapy significantly enhances survival rates for advanced non-small cell lung cancer patients.

A phase 2 study reveals autologous TIL therapy's potential to stabilize recurrent head and neck cancer, offering hope for improved treatment options.

Combination therapy of casdatifan and cabozantinib shows promising efficacy and manageable safety in advanced clear cell ...

Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating ...

Nemvaleukin alfa shows promising antitumor activity in advanced melanoma and renal cell carcinoma, with manageable safety in ...

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion-mutated NSCLC, ...

ABBV-706 shows promising efficacy and manageable safety in relapsed/refractory small cell lung cancer, offering hope for ...

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in ...